RCP

GRAFALON (antilymphocyte immunoglobulin) is indicated, in association with other immunosuppressant drugs, to suppress immunocompetent cells, which are the cause of acute rejection or the Graft-versus-host disease.

• To prevent the acute transplantation rejection in patients subjected to solid organ transplantation.
• Grafalon is indicated, in association with other immunosuppressants (e.g. glucocorticosteroids, purine antagonists, calcineurin inhibitors or mTOR inhibitors), to enhance the immune suppression following the allogenic transplantation of solid organs.
• The treatment of acute corticosteroid-resistant rejection occurring after the allogenic transplantation of solid organs.
• Grafalon is recommended in the treatment of acute corticosteroid-resistant rejection occurring after the allogenic transplantation of solid organs, if the therapeutic effect of methylprednisolone is unsatisfactory.
• Prevention of the Graft-versus-host disease (GVHD) disease in adults, following allogenic stem cell transplantation (SCT), Grafalon is indicated to prevent the Graft-versus-host disease (GVHD) in adults with malign hematologic diseases, following stem cell transplantations from compatible unrelated donors, in association with the standard cyclosporine A/methotrexate prophylaxis.

Read more